As complex as reverse-payment antitrust lawsuits can be, the one being litigated against generic drug maker Ranbaxy over its settlement with Cephalon can be broken down to the difference between fine and coarse salt, said one of the attorneys bringing the case.
Foley & Lardner attorney James Matthews, who is representing fellow generic drug maker Apotex, told the jury set to preside over Apotex v. Cephalon that the name-brand drugmaker Cephalon essentially bought coarse kosher salt and then told the U.S. patent office that it invented the finer version of the same substance.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
